https://maxanim.com/array-bridge-elisa/synabridge-elisa-for-synagis-biosimilar-comparison-ab000206/
SynaBridge ELISA (for Synagis Biosimilar comparison) | AB000206 | Array Bridge
elisasynagisbiosimilarcomparisonarray
https://www.ndf.gov.sg/about-drugs/active-ingredient/m01330/
Palivizumab [Synagis] | National Drug Formulary
Active ingredient: Palivizumab
drug formularysynagisnational
https://pharmaceutical-business-review.com/news/astrazeneca-synagis-us-rights-sobi/
AstraZeneca to sell Synagis US rights to Sobi for $1.5bn -
Nov 16, 2018 - AstraZeneca will offload the US rights of its respiratory drug Synagis (palivizumab) to Sobi in a cash-cum-stock deal worth $1.5bn.
to sellastrazenecasynagisusrights
https://www.gentaur-italy.com/shop/0708-tab-009-10mg-anti-rsv-therapeutic-antibody-synagis-palivizumab-10-mg-5598
Anti-RSV Therapeutic Antibody (Synagis) Palivizumab - 10 mg | Gentaur Italia
therapeutic antibodyrsvsynagismggentaur